Microenvironmental G protein-coupled estrogen receptor-mediated glutamine metabolic coupling between cancer-associated fibroblasts and triple-negative breast cancer cells governs tumour progression

Abstract

	1. Estrogen-activated GPER in CAFs enhances GLUL and LDHB expression via the cAMP/PKA/CREB signalling, facilitating glutamine production and utilization.
	2. Microenvironmental GPER-induced glutamine serves as a crucial mediator of metabolic coupling between CAFs and TNBC cells, boosting tumour progression by enhancing mitochondrial function.
	3. Targeting the glutamine metabolic coupling triggered by estrogen/GPER/GLUL signalling in CAFs is a promising therapeutic strategy for TNBC treatment.

Keywords

CAFs / glutamine metabolism / GPER / TNBC / tumour progression

References

[1] SiegelRL, MillerKD, WagleNS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73: 17-48.

[2] TangY, TianW, ZhengS, et al. Dissection of FOXO1-induced LYPLAL1-DT impeding triple-negative breast cancer progression via mediating hnRNPK/β-catenin complex. Research (Washington, DC). 2023; 6: 0289.

[3] GanesanK, XuC, WuJ, et al. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway. Sci China Life Sci. 2024; 67: 1849-1866.

[4] OuX, TanY, XieJ, et al. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer. Drug Resist Update. 2024; 73: 101063.

[5] FanY, HeS. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manage Res. 2022; 14: 1-17.

[6] HuD, LiZ, ZhengB, et al. Cancer-associated fibroblasts in breast cancer: challenges and opportunities. Cancer Commun (London, England). 2022; 42: 401-434.

[7] ColoffJL, MurphyJP, BraunCR, et al. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab. 2016; 23: 867-880.

[8] HuangM, XiongD, PanJ, et al. Targeting glutamine metabolism to enhance immunoprevention of EGFR-driven lung cancer. Adv Sci. 2022; 9: e2105885.

[9] Mestre-FarreraA, Bruch-Oms M, PeñaR, et al. Glutamine-directed migration of cancer-activated fibroblasts facilitates epithelial tumor invasion. Cancer Res. 2021; 81: 438-451.

[10] PachnisP, WuZ, FaubertB, et al. In vivo isotope tracing reveals a requirement for the electron transport chain in glucose and glutamine metabolism by tumors. Sci Adv. 2022; 8: eabn9550.

[11] JiangW, OuyangX, JiZ, et al. The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer. Cancer Lett. 2023; 556: 216064.

[12] WojtowiczW, Wróbel A, PyziakK, et al. Evaluation of MDA-MB-468 Cell Culture Media Analysis in Predicting Triple-Negative Breast Cancer Patient Sera Metabolic Profiles. Metabolites. 2020; 10.

[13] YagerJD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006; 354: 270-282.

[14] LiuL, LiuS, LuoH, et al. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells. Aging. 2021; 13: 16178-16197.

[15] YinJ, TuG, PengM, et al. GPER-regulated lncRNA-Glu promotes glutamate secretion to enhance cellular invasion and metastasis in triple-negative breast cancer. FASEB J. 2020; 34: 4557-4572.

[16] DongH, ZengX, XuJ, et al. Advances in immune regulation of the G protein-coupled estrogen receptor. Int Immunopharmacol. 2024; 136: 112369.

[17] YuT, ChengH, DingZ, et al. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells. Mol Cell Endocrinol. 2020; 506: 110762.

[18] XuT, MaD, ChenS, et al. High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes. NPJ Breast Cancer. 2022; 8: 100.

[19] PupoM, Vivacqua A, PerrottaI, et al. The nuclear localization signal is required for nuclear GPER translocation and function in breast cancer-associated fibroblasts (CAFs). Mol Cell Endocrinol. 2013; 376: 23-32.

[20] YuT, YangG, HouY, et al. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance. Oncogene. 2017; 36: 2131-2145.

[21] WangL, HouY, SunY, et al. c-Ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion. Molecular oncology. 2013; 7: 1116-1128.

[22] LuoH, YangG, YuT, et al. GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts. Endocr Relat Cancer. 2014; 21: 355-369.

[23] WenS, HouY, FuL, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling. Cancer Lett. 2019; 442: 320-332.

[24] BerteroT, OldhamWM, GrassetEM, et al. Tumor-stroma mechanics coordinate amino acid availability to sustain tumor growth and malignancy. Cell Metab. 2019; 29: 124-140.e110.

[25] DamianiC, Colombo R, GaglioD, et al. A metabolic core model elucidates how enhanced utilization of glucose and glutamine, with enhanced glutamine-dependent lactate production, promotes cancer cell growth: the WarburQ effect. PLoS Comput Biol. 2017; 13: e1005758.

[26] YangL, Venneti S, NagrathD. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017; 19: 163-194.

[27] LiuL, ZhangX, DingH, et al. Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS. Oncogene. 2021; 40: 3548-3563.

[28] CluntunAA, LukeyMJ, CerioneRA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017; 3: 169-180.

[29] McCarthySA, MufsonRA, PearceEJ, Rathmell JC, HowcroftTK. Metabolic reprogramming of the immune response in the tumor microenvironment. Cancer Biol Ther. 2013; 14: 315-318.

[30] CaoS, HungYW, WangYC, et al. Glutamine is essential for overcoming the immunosuppressive microenvironment in malignant salivary gland tumors. Theranostics. 2022; 12: 6038-6056.

[31] SunK, TangS, HouY, et al. Oxidized ATM-mediated glycolysis enhancement in breast cancer-associated fibroblasts contributes to tumor invasion through lactate as metabolic coupling. EBioMedicine. 2019; 41: 370-383.

[32] ChengSB, Graeber CT, QuinnJA, FilardoEJ. Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids. 2011; 76: 892-896.

[33] PollettaL, Vernucci E, CarnevaleI, et al. SIRT5 regulation of ammonia-induced autophagy and mitophagy. Autophagy. 2015; 11: 253-270.

[34] WangY, FanS, LuJ, et al. GLUL promotes cell proliferation in breast cancer. J Cell Biochem. 2017; 118: 2018-2025.

[35] RosatiA, Poliani PL, TodeschiniA, et al. Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol. 2013; 15: 618-625.

[36] FanS, WangY, ZhangZ, et al. High expression of glutamate-ammonia ligase is associated with unfavorable prognosis in patients with ovarian cancer. J Cell Biochem. 2018; 119: 6008-6015.

[37] YangL, Achreja A, YeungTL, et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab. 2016; 24: 685-700.

[38] AiC, SunX, XiaoS, et al. CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling. Journal of nanobiotechnology. 2023; 21: 214.

[39] ZhouWX, ChenC, LiuXQ, et al. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem. 2021; 210: 112980.

[40] WangVM, Ferreira RMM, AlmagroJ, et al. CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth. Nat Cell Biol. 2019; 21: 1425-1435.

[41] ChenY, TianY, JinG, et al. Lobetyolin inhibits the proliferation of breast cancer cells via ASCT2 down-regulation-induced apoptosis. Hum Exp Toxicol. 2021; 40: 2074-2086.

[42] LiJ, LiX, WuL, PeiM, LiH, JiangY. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells. Cell Biol Int. 2019; 43: 921-930.

[43] GeY, YanX, JinY, et al. MiRNA-192 [corrected] and miRNA-204 directly suppress lncRNA HOTTIP and interrupt GLS1-mediated glutaminolysis in hepatocellular carcinoma. PLoS Genet. 2015; 11: e1005726.

[44] XiJ, SunY, ZhangM, et al. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway. Exp Cell Res. 2019; 381: 1-9.

[45] BrownTP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020; 206: 107451.

[46] TaliaM, Cirillo F, ScordamagliaD, et al. The G protein estrogen receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer. Journal of experimental & clinical cancer research : CR. 2024; 43: 171.

[47] ChenB, ChanWN, XieF, et al. The molecular classification of cancer-associated fibroblasts on a pan-cancer single-cell transcriptional atlas. Clin Transl Med. 2023; 13: e1516.

[48] CordsL, de Souza N, BodenmillerB. Classifying cancer-associated fibroblasts-The good, the bad, and the target. Cancer Cell. 2024; 42: 1480-1485.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.